Stockscreener 앱 받기
1.03
3.74%
-0.04
Nektar Therapeutics 주식(NKTR)의 최신 뉴스
Nektar presents preclinical data on NKTR-422 at ACR conference - TipRanks
Nektar Therapeutics Presents First Preclinical Data from Novel CSF-1 Program, NKTR-422, at 2024 American College of Rheumatology (ACR) Convergence - Kilgore News Herald
Eventide Asset Management's Strategic Acquisition of Nektar Ther - GuruFocus.com
Deep Track Capital, LP Reduces Stake in Nektar Therapeutics - GuruFocus.com
Multiple Catalysts Ahead For Nektar Therapeutics (NASDAQ:NKTR) - Seeking Alpha
NK Cell Therapy Clinical Trial Pipeline Appears Robust With 140+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Yahoo Finance
Nektar Therapeutics to sell Alabama facility to Ampersand - MSN
NKTR-255 Shows Promise for Reversing Radiation-Induced Lymphopenia in NSCLC - Targeted Oncology
Nektar Therapeutics (NASDAQ:NKTR) Just Reported And Analysts Have Been Lifting Their Price Targets - Yahoo Canada Finance
Nektar Therapeutics (NASDAQ:NKTR) Q3 2024 Earnings Call Transcript - Insider Monkey
Nektar Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Earnings call: Nektar Therapeutics progresses with key clinical studies By Investing.com - Investing.com UK
Nektar Therapeutics (NKTR) Quarterly 10-Q Report - Quartz
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus - Yahoo Finance
Nektar reports NKTR-255 boosts lymphocyte recovery By Investing.com - Investing.com Australia
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Str - GuruFocus.com
Nektar Therapeutics (NKTR) Q3 2024 Earnings Call Highlights: Strategic Moves and Financial Outlook - Yahoo Finance
Nektar: Q3 Earnings Snapshot - The Washington Post
Nektar Therapeutics Reports Stable Q3 Earnings for 2024 - TipRanks
Nektar Therapeutics Q3 2024 Earnings: Revenue Surpasses Estimate - GuruFocus.com
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Nektar: Q3 Earnings Snapshot | National Business News | voiceofalexandria.com - Voice Of Alexandria
Nektar Therapeutics (NKTR) Tops Q3 EPS by 2c - StreetInsider.com
Nektar Therapeutics Narrows Losses, Sells Manufacturing Facility for $90M in Q3 | NKTR Stock News - StockTitan
Nektar Therapeutics Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Nektar releases promising phase 2 results for NKTR-255 in lymphopenia - MSN
Rx Rundown: Avid Biosciences, Novo Nordisk, Zealand Pharma and more - MM+M Online
Nektar reports NKTR-255 boosts lymphocyte recovery - Investing.com
Nektar Therapeutics (NKTR) and Collaborators Present Late-breaking Results from Phase 2 Study of NKTR-255 - StreetInsider.com
Nektar's NKTR-255 Shows Breakthrough Results in Cancer Treatment Study with MD Anderson | NKTR Stock News - StockTitan
Nektar reports Q3 EPS (18c), consensus (20c) - TipRanks
Nektar Therapeutics to Participate in Upcoming Investor Conferences - Longview News-Journal
Moderna said to shuffle sales leadership; Vertex records first Casgevy sale - Yahoo Finance
Ampersand’s Acquisition of a Nektar’s Manufacturing Facility and Reagent Supply Business - Global Legal Chronicle
Nektar sells its PEGylation reagent manufacturing business - The Pharma Letter
Nektar divests manufacturing site and reagent arm for $90M - Endpoints News
Nektar announces agreement to sell Alabama manufacturing facility and reagent supply business - MSN
NKTRNektar Therapeutics Latest Stock News & Market Updates - StockTitan
Eczema Drug Developer Nektar Gains Analyst Confidence With 400% Upside Potential - Benzinga
Nektar pads wallet with $90M manufacturing plant sale to Ampersand - FiercePharma
Nektar divests Alabama facility to Ampersand for $90 million By Investing.com - Investing.com Canada
Nektar Therapeutics Sells Manufacturing Facility for $90M - TipRanks
Nektar divests Alabama facility to Ampersand for $90 million - Investing.com
Nektar Therapeutics (NASDAQ:NKTR) Now Covered by Piper Sandler - MarketBeat
Nektar Therapeutics (NKTR) to Sell Commercial PEGylation Reagent Manufacturing Business in Alabama - StreetInsider.com
Nektar Announces Definitive Agreement with Ampersand Capital Partners to Sell Its Commercial PEGylation Reagent Manufacturing Business in Alabama - StockTitan
Piper Sandler Starts Nektar Therapeutics (NKTR) at Overweight - StreetInsider.com
Ampersand Management LLC entered into an Asset Purchase Agreement to acquire Manufacturing Facility and Reagent Supply Business in Huntsville, Alabama of Nektar Therapeutics from Nektar Therapeutics for $90 million. - Marketscreener.com
Nektar Therapeutics (NKTR) Stock Surges Amidst Mixed Financials - GuruFocus.com
Nektar Therapeutics (NKTR) Scheduled to Post Earnings on Thursday - MarketBeat
Nektar to Announce Financial Results for the Third Quarter 2024 on Thursday, November 7, 2024, After Close of U.S.-Based Financial Markets - Longview News-Journal
Nektar Therapeutics (NASDAQ:NKTR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Nektar reports positive Phase 1b skin disease study results By Investing.com - Investing.com South Africa
Nektar reports positive Phase 1b skin disease study results - Investing.com India
Nektar Therapeutics (NKTR) Announces Publication of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases - StreetInsider.com
Nektar Announces Publication in Nature Communications of Results from Phase 1b Studies of Rezpegaldesleukin in Two Inflammatory Skin Diseases - StockTitan
3.66%
1.11%
자본화:
|
볼륨(24시간):